{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-028048","form_type":"8-K","ticker":"ENVB","cik":"0000890821","company_name":"Enveric Biosciences, Inc.","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.903404+00:00","generated_at":"2026-06-11T13:37:01.797902+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Enveric Biosciences Q2 net loss $6.4M; cost cuts extend runway into Q1 2024","bullets":["Net loss of $6.40M ($3.04 per share) vs $2.87M ($2.73) in Q2 2022.","Cash & equivalents $7.08M at June 30; net cash used in operations $4.47M.","Cost reduction plan announced to extend financial runway into Q1 2024.","Multiple USPTO Notices of Allowance for composition of matter claims covering EB-373, EVM201, and EVM301 Series.","On track to identify EVM301 Series lead candidate by year-end 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-028048","json":"https://secwatch.observer/filing/0001493152-23-028048.json","markdown":"https://secwatch.observer/filing/0001493152-23-028048.md","text":"https://secwatch.observer/filing/0001493152-23-028048.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/890821/000149315223028048/0001493152-23-028048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/890821/000149315223028048/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T13:37:01.797902+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8ed6c97f3546c64318115567445f8a9905df0e91","claim":"Enveric Biosciences, Inc. reported second quarter of 2023 ended June 30, 2023 results: net income $6.40 million, EPS $3.04.","evidence_excerpt":"Net loss attributable to shareholders was $6.40 million for the second quarter ended June 30, 2023, including $1.64 million in net non-cash expenses, with a basic and diluted loss per share of $3.04, as compared to a net loss of $2.87 million and non-cash income of $1.04 million, with primary and diluted loss per share of $2.73 per share for the quarter ended June 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/890821/000149315223028048/0001493152-23-028048-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter of 2023 ended June 30, 2023"},{"label":"Net income","value":"$6.40 million"},{"label":"EPS","value":"$3.04"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}